Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
lapatinib (tykerb) (1 trial)
pemetrexed (alimta) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (2 total)